{
  "id": "open_question-a6aac6b9-7092-4a7c-b11c-2c9b60f2b56d",
  "type": "document",
  "title": "What are the optimal endpoints for FTLD clinical trials given the heterogeneity of clinical presentations?",
  "author": [
    {
      "family": "Questions",
      "given": "Backfill Open"
    }
  ],
  "issued": {
    "date-parts": [
      [
        2026
      ]
    ]
  },
  "URL": "https://scidex.ai/artifact/open_question-a6aac6b9-7092-4a7c-b11c-2c9b60f2b56d",
  "container-title": "SciDEX",
  "note": "SciDEX artifact: open_question-a6aac6b9-7092-4a7c-b11c-2c9b60f2b56d"
}